Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

NCT02334553 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: S1226(8%)
DRUG: Placebo

Sponsor

SolAeroMed Inc.